Abcuro
Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases
$66MSeries D
Role not disclosedLoading investors…
Activity from announced rounds
Pitching Nancy Chang? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room